Dr. Douglas Fambrough
President & CEO, Dicerna Pharmaceuticals
Fambrough co-founded Dicerna in 2007 and has served as president and CEO since 2010. Prior to Dicerna, he specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a venture capital firm. He and two other investors created Sirna Therapeutics, a first-generation RNA interference pioneer and served on the Sirna's board until its acquisition by Merck in 2006.
- October 2020
Added to: TScan Therapeutics - Waltham, MA
TScan Therapeutics is a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient's own T cells to recognize shared cancer targets. The TScan technology platform also can be used to target existing antigens and to predict previously uncharacterized off-targets of known TCRs.